ClinicalTrials.gg
CompletedNCT07857005Updated Oct 5, 2026

Dexmedetomidine vs Propofol Sedation in Endovascular Aortic Repair

An observational study in Abdominal Aortic Aneurysm and Acute Kidney Injury, sponsored by Bursa City Hospital. Completed at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Bursa City Hospital · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
282
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Endovascular aortic repair (EVAR) is increasingly performed under local anesthesia with intravenous sedation, but the optimal sedative agent has not been established. Dexmedetomidine provides cooperative sedation with minimal respiratory depression and may have renoprotective effects, whereas propofol is widely used but can cause respiratory depression and hypotension.

This single-center retrospective cohort study compares dexmedetomidine-based and propofol-based sedation in adult patients who underwent EVAR under local anesthesia and sedation at Bursa City Hospital. The primary outcome is postoperative acute kidney injury (AKI) defined by KDIGO serum creatinine criteria. Secondary outcomes include intensive care unit (ICU) admission, ICU length of stay, hospital length of stay, and in-hospital mortality.

Read the detailed description

Background: Acute kidney injury develops in approximately 15-20% of patients after EVAR and is associated with worse short- and long-term survival. Proposed renoprotective mechanisms of dexmedetomidine include attenuation of sympathoadrenal activity, suppression of renin release, and support of renal vasodilation. Randomized data in endovascular repair of type B aortic dissection and meta-analyses in cardiac and aortic surgery suggest a reduction in AKI with dexmedetomidine, but data on its use as the primary sedative agent during EVAR under local anesthesia are limited.

Hypothesis: Through its sympatholytic effect and more stable perioperative hemodynamics, dexmedetomidine-based sedation is associated with a lower incidence of postoperative AKI and shorter ICU and hospital length of stay compared with propofol-based sedation.

Design and setting: Single-center, retrospective cohort study at Bursa City Hospital, Bursa, Türkiye, reported according to the STROBE statement. Records of all adult patients who underwent EVAR in the operating room between 18 October 2019 and 5 August 2026 are reviewed. Patients are allocated to two groups according to the sedative agent received (dexmedetomidine or propofol). The choice of sedative agent was at the discretion of the attending anesthesiologist.

Anesthetic management (institutional protocol): Standard ASA monitoring and radial arterial catheterization under local anesthesia, oxygen 4-6 L/min via nasal cannula, and local anesthetic infiltration of vascular access sites. Dexmedetomidine group: 0.5 µg/kg IV loading dose over 10 minutes followed by 0.2-1.0 µg/kg/h infusion. Propofol group: IV infusion titrated to the lowest dose providing immobility while preserving spontaneous breathing and airway patency, with 10 mg IV boluses as needed. After the procedure, patients with a Modified Aldrete score of 9 or higher are transferred to the ward and others to the ICU.

Data collection: Data are obtained from electronic health records, anesthesia charts, ICU records, and institutional laboratory reports, including age, sex, ASA physical status, comorbidities (hypertension, diabetes mellitus, coronary artery disease, asthma/COPD, congestive heart failure, cerebrovascular disease, chronic kidney disease), baseline serum creatinine (lowest value within the preceding 3 months), serum creatinine and eGFR (CKD-EPI) on postoperative days 1, 2 and 7, ICU admission, ICU and hospital length of stay, and in-hospital mortality.

Statistical analysis: No formal sample size calculation is performed; all eligible patients during the study period are included. Continuous variables are compared with Welch's t-test or Mann-Whitney U test, and categorical variables with the chi-square or Fisher's exact test. Absolute risk difference, relative risk and odds ratio with 95% confidence intervals are calculated for the primary outcome. Multivariable logistic regression adjusted for sedative agent, age, sex, baseline eGFR, and comorbidities associated with AKI at p\<0.10 in univariable analysis is used to account for confounding. Model fit is assessed with the Hosmer-Lemeshow test and discrimination with the area under the ROC curve. Two-sided p\<0.05 is considered significant.

02

Conditions studied

  • Abdominal Aortic Aneurysm
  • Acute Kidney Injury

Keywords

  • Endovascular Aneurysm Repair
  • EVAR
  • Dexmedetomidine
  • Propofol
  • Conscious Sedation
  • Monitored Anesthesia Care
  • Local Anesthesia
  • KDIGO
03

In context

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

This study's enrollment of 282 is above the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.

Browse Aortic Aneurysm, Abdominal studies →

Lead sponsor

Bursa City Hospital is the lead sponsor of 71 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who underwent endovascular aortic repair under local anesthesia and intravenous sedation in the operating room of Bursa City Hospital between 18 October 2019 and 5 August 2026.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Underwent endovascular aortic repair in the operating room of Bursa City Hospital between 18 October 2019 and 5 August 2026
  • Received local anesthesia with dexmedetomidine-based or propofol-based intravenous sedation

Exclusion criteria

Exclusion Criteria:

  • General anesthesia
  • Emergency procedures
  • Missing data in medical records
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
282 participants (actual)
Patient registry
No

Groups and cohorts

  • Dexmedetomidine Group

    Adult patients who underwent elective EVAR under local anesthesia with dexmedetomidine-based intraoperative sedation.

    Drug: Dexmedetomidine

  • Propofol Group

    Adult patients who underwent elective EVAR under local anesthesia with propofol-based intraoperative sedation.

    Drug: propofol

Interventions

  • Intravenous 0.5 µg/kg loading dose over 10 minutes followed by 0.2-1.0 µg/kg/h maintenance infusion throughout the procedure, in addition to local anesthetic infiltration of vascular access sites.

  • Intravenous infusion titrated to the lowest dose providing immobility while preserving spontaneous breathing and airway patency, with 10 mg IV boluses as needed, in addition to local anesthetic infiltration of vascular access sites.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative acute kidney injury (AKI)

    AKI defined by the 2012 KDIGO serum creatinine criteria: an increase of at least 0.3 mg/dL (26.5 µmol/L) from baseline within 48 hours (highest of postoperative day 1 and 2 values), or an increase to at least 1.5 times baseline within 7 days (highest of postoperative day 1, 2 and 7 values). Baseline creatinine is the lowest value within the preceding 3 months. AKI is staged according to KDIGO (stage 1-3). Urine output criteria are not used.

    Time frame: From the end of the procedure through postoperative day 7

Secondary outcomes

  1. ICU admission

    Proportion of patients requiring intensive care unit admission after the procedure.

    Time frame: Within 24 hours after the end of the procedure

  2. ICU length of stay

    Duration of ICU stay in hours among patients admitted to the ICU; prolonged ICU stay is also assessed using thresholds of more than 24 hours and more than 48 hours.

    Time frame: From ICU admission to ICU discharge, up to 30 days

  3. Hospital length of stay

    Duration of postoperative hospital stay in hours.

    Time frame: From the end of the procedure to hospital discharge, up to 180 days

  4. In-hospital mortality

    Death from any cause during the index hospitalization.

    Time frame: From the procedure until hospital discharge, up to 180 days

07

Study locations

2 sites
  • Bursa City Hospital Scientific Research Ethics Committee
    Bursa, Bursa/nilufer 16250, Turkey (Türkiye)
  • Bursa City Hospital
    Bursa, Nilufer 16110, Turkey (Türkiye)
08

References and documents

Publications

  • Cho JS, Shim JK, Soh S, Kim MK, Kwak YL. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int. 2016 Mar;89(3):693-700. doi: 10.1038/ki.2015.306. PubMed 26444030 ↗
  • Hashmi TM, Ashraf H, Burhan M, Zia R, Ahmed M, Ahmed R, Aized MT. Effects of Dexmedetomidine on Acute Kidney Injury and Perioperative Outcomes in Aortic Vascular Surgery: A Systematic Review and Meta-Analysis. Semin Cardiothorac Vasc Anesth. 2025 Dec;29(4):291-299. doi: 10.1177/10892532251346645. Epub 2025 Jun 25. PubMed 40563160 ↗
  • Shan XS, Dai HR, Zhao D, Yang BW, Feng XM, Liu H, Peng K, Ji FH. Dexmedetomidine reduces acute kidney injury after endovascular aortic repair of Stanford type B aortic dissection: A randomized, double-blind, placebo-controlled pilot study. J Clin Anesth. 2021 Dec;75:110498. doi: 10.1016/j.jclinane.2021.110498. Epub 2021 Sep 3. PubMed 34488061 ↗
  • Jhaveri KD, Saratzis AN, Wanchoo R, Sarafidis PA. Endovascular aneurysm repair (EVAR)- and transcatheter aortic valve replacement (TAVR)-associated acute kidney injury. Kidney Int. 2017 Jun;91(6):1312-1323. doi: 10.1016/j.kint.2016.11.030. Epub 2017 Mar 17. PubMed 28318632 ↗
  • Geisbusch P, Katzen BT, Machado R, Benenati JF, Pena C, Tsoukas AI. Local anaesthesia for endovascular repair of infrarenal aortic aneurysms. Eur J Vasc Endovasc Surg. 2011 Oct;42(4):467-73. doi: 10.1016/j.ejvs.2011.05.018. Epub 2011 Jun 20. PubMed 21693382 ↗
  • Ruppert V, Leurs LJ, Steckmeier B, Buth J, Umscheid T. Influence of anesthesia type on outcome after endovascular aortic aneurysm repair: an analysis based on EUROSTAR data. J Vasc Surg. 2006 Jul;44(1):16-21; discussion 21. doi: 10.1016/j.jvs.2006.03.039. PubMed 16828420 ↗
  • De Virgilio C, Romero L, Donayre C, Meek K, Lewis RJ, Lippmann M, Rodriguez C, White R. Endovascular abdominal aortic aneurysm repair with general versus local anesthesia: a comparison of cardiopulmonary morbidity and mortality rates. J Vasc Surg. 2002 Nov;36(5):988-91. doi: 10.1067/mva.2002.128314. PubMed 12422110 ↗
  • Brown BJ, Zakhary S, Rogers L, Ellis-Stoll C, Gable D, Ramsay MA. Use of dexmedetomidine versus general anesthesia for endovascular repair of abdominal aortic aneurysms. Proc (Bayl Univ Med Cent). 2006 Jul;19(3):213-5. doi: 10.1080/08998280.2006.11928164. PubMed 17252035 ↗

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared. De-identified data are available from the corresponding author upon reasonable request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 5, 2026
StartActual
Sep 1, 2026
Primary completionActual
Sep 15, 2026
CompletionActual
Sep 15, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857005
Lead sponsor
Bursa City Hospital
Responsible party
eralp çevikkalp (Associate Professor, Bursa City Hospital) — Principal investigator
First posted
Oct 5, 2026
Start date
Sep 1, 2026
Primary completion
Sep 15, 2026
Completion
Sep 15, 2026
Last update
Oct 5, 2026

Study contacts

Esat M DEMIREL, MD
study chair · Bursa City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion